Dishman Carbogen Amcis Ltd (DCAL) Q1FY26 Concall Summary - Jun-2025 Qtr
Performance Overview
- Dishman Carbogen Amcis Ltd. reported strong revenue growth of 35% YoY, reaching Rs. 708 crores in Q1 FY26.
- The company achieved a significant improvement in EBITDA margin to 19.9% compared to 5.8% in Q1 FY25.
- Successful USFDA inspection at the Naroda site with zero observations, strengthening regulatory compliance.
- Expansion projects in Switzerland are progressing as planned, including a co-investment agreement with a Japanese partner.
- The company is actively increasing its sales force, particularly in the U.S., Japan, and China, and witnessing a positive impact on order income.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.